Clinical Trial

Polynucleotides and Hyaluronic Acid vs Enamel Matrix Proteins in the Treatment of Intrabony Defects

Study acronym: PN-HAVSEMPIND
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to compare two periodontal regenerative treatments in adults with Stage III or IV periodontitis and infrabony periodontal defects ≥3 mm. The study aims to determine whether hyaluronic acid and polynucleotides (Regenfast®) combined with bovine bone graft material (Bio-Oss®) provides similar or improved periodontal regeneration compared with enamel matrix derivative proteins (Emdogain®) combined with Bio-Oss®. Researchers will evaluate: * Periodontal healing and bone regeneration * Changes in probing depth, clinical attachment level, gingival recession, and tooth mobility * Radiographic bone fill * Survival of treated teeth after 1, 3, and 5 years Participants will: * Receive initial periodontal treatment and oral hygiene instruction * Undergo clinical and radiographic evaluation * Receive minimally invasive periodontal regenerative surgery under local anesthesia * Be randomly assigned to receive either Regenfast® + Bio-Oss® or Emdogain® + Bio-Oss® * Attend follow-up visits with periodontal examinations and radiographs over 5 years
Trial Details
NCT Number NCT07589959
Lead Sponsor Shashi Dadlani
Conditions Periodontal Bone Loss, Periodontal Defect, Periodontitis Stage III, Periodontitis Stage IV
Enrollment 40 participants
Start Date 2026-05
Primary Completion 2031-05-22 (estimated)
Study Completion 2031-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-15